Gonçalo Vieira

Dr. Gonçalo Vieira Specialist Nuclear Medicine


Years of Experience : Portugal

Nationality :

Languages Known : Portuguese, English, Spanish

Book Appointment

Biography

Dr. Gonçalo Vieira is a distinguished Nuclear Medicine Specialist with a profound expertise in radionuclide diagnosis and therapy, particularly in the management of endocrine and neuroendocrine tumors. Over the course of his career, Dr. Vieira has been instrumental in implementing cutting-edge therapies, including the use of Lutetium-PSMA for prostate cancer treatment. His dedication to advancing medical treatments has significantly contributed to improving patient outcomes in the field of Nuclear Medicine.  Dr. Vieira earned his Fellowship from the European Board of Nuclear Medicine, underscoring his commitment to excellence and continuous learning. He has an extensive background in clinical research, regularly participating as a speaker at prominent scientific conferences and contributing to the development of innovative treatment protocols. His involvement in research has not only advanced the understanding of nuclear medicine but also paved the way for new therapeutic applications. In addition to his clinical and research accomplishments, Dr. Vieira is a passionate educator. He serves as a visiting lecturer at Porto University, where he shares his knowledge and experience with the next generation of medical professionals. His role as a mentor and educator reflects his dedication to fostering a collaborative learning environment and promoting the highest standards in medical education. Dr. Vieira’s expertise, combined with his collaborative approach and commitment to excellence, positions him as a leader in the field of Nuclear Medicine. His work continues to impact patient care positively, making significant strides in the diagnosis and treatment of complex medical conditions. 

Awards & Achievements

  • Best Study Award at the XVII Portuguese Congress of Nuclear Medicine (Porto, November 2019).
  • Best Study Award at the 12th World Congress of the World Federation of Nuclear Medicine and Biology (Melbourne, April 2018).
  • Sponsorship for a 3-month program at Peter McCallum Cancer Centre (2018) by Liga Portuguesa Contra o Cancro (Portuguese League Against Cancer).

Research & Publications

  • 68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma - novel correlations with tumoral biomarkers; Endocrine. 2019 May; 64(2):322-329 (co-author).
  • Intra-individual Comparison of 68Ga-PSMA-11 and 18F-DCFPyL Normal-Organ Biodistribution; Cancer Imaging. 2019 May 15; 19(1):23 (first author).
  • Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review; Journal of Endocrinological Investigation. 2019 Mar; 42(3):249-260 (co-author).
  • Treatment of Neuroendocrine Tumors with 177Lu-DOTA-TATE; XVII Portuguese Congress of Nuclear Medicine, Porto, Portugal, November 2019.
  • Response Assessment to Immunotherapy with PD1 Inhibitors Using Metabolic Tumor Volume on 18F-FDG PET/CT; 32nd Annual Congress of the European Association of Nuclear Medicine - EANM'19, Barcelona, Spain, October 2019.
  • Results of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Patients with Head and Neck Paragangliomas; 12th World Congress of the World Federation of Nuclear Medicine and Biology, Melbourne, Australia, April 2018.

Education & Training

  • Master’s Degree in Medicine (MSc)
  • ICBAS, University of Porto: 2008 – 2014.
  • Nuclear Medicine Residency Program
  • IPO Porto, Porto, Portugal: 2016 – Aug 2020.
  • Fellowship of the European Board of Nuclear Medicine
  • Examination held in Hamburg, Germany: October 2024.
  • Peter MacCallum Cancer Centre, Melbourne, Australia: May 2018 – July 2018.
  • CH Médio Ave, Famalicão, Portugal: Jan 2015 – Dec 2015.

Membership

  • International Cancer Imaging Society (Sep/2018 – Present).
  • Portuguese Society of Nuclear Medicine (Nov/2017 – Present).
  • Society of Nuclear Medicine and Molecular Imaging (Jan/2017 – Present).
  • European Association of Nuclear Medicine (Jan/2016 – Present).

Blogs